Lutetium-177 (Lu-177) Market Market Size, Share, Growth, and Industry Analysis, By Type (Non-carrier-added, Carrier-added), By Application (Nuclear Therapy, Others), Regional Insights and Forecast From 2026 To 2035
Lutetium-177 (Lu-177) Market Overview
The global lutetium-177 (Lu-177) market size is estimated at USD 2880.71 million in 2026 and is projected to reach USD 11559.76 million by 2035, registering a CAGR of 16.9% during the forecast period. Market growth is driven by increasing adoption of targeted radioligand therapies, rising cancer treatment demand, and advancements in nuclear medicine. Expanding isotope production capacity, growing clinical research activities, and increasing investments in radiopharmaceutical development further support market expansion worldwide.
The United States is the largest national contributor to the Lu-177 market. FDA-approved radioligand therapies such as Lutathera and Pluvicto each use a standard 7.4 GBq dose per treatment cycle. Domestic production is also strengthening, with SHINE Technologies operating its Cassiopeia facility in Wisconsin at a capacity of 100,000 doses per year. A wide network of nuclear medicine departments, familiarity with reimbursement pathways, and an active clinical trial environment keep demand for non-carrier-added Lu-177 high. North America holds a 41.3% share of the global market, and the United States accounts for most of that regional demand.
Key Findings
- Market Size and Forecast: Valued at USD 2880.71 million in 2026, the market is expected to hit USD 11559.76 million by 2035 at 16.9% CAGR.
- Type Leadership: Non-carrier-added Lu-177 leads with 71.5% share, driven by higher radionuclidic purity, high specific activity, and radiolabeling consistency.
- Application Leadership: Nuclear therapy dominates with 83.2% share, supported by rising prostate cancer and neuroendocrine tumor radioligand treatment demand worldwide.
- Key Company Landscape: Advanced Accelerator Applications (Novartis) and Eckert & Ziegler Strahlen lead through commercial radioligand therapies and GMP-grade n.c.a. Lu-177 supply capacity.
- Leading Region: North America leads with 41.3% share, backed by approved radioligand therapies, advanced nuclear medicine infrastructure, and domestic isotope production.
Latest Trends
A leading trend in the Lu-177 market is the shift toward non-carrier-added production through ytterbium-176 irradiation. This route avoids the long-lived lutetium-177m impurity, which has a half-life of 160 days and complicates waste handling at hospitals. Producers are also securing enrichment capacity for ytterbium-176, because natural ytterbium contains only 12.9% of this isotope.
Another trend is geographic diversification of supply. Production sites in North America, Europe, Australia, and South Africa are being linked through licensing and long-term supply agreements. Radiopharmaceutical developers are also moving Lu-177 pipelines beyond prostate cancer and neuroendocrine tumors into additional solid tumor indications.
Market Dynamics
DRIVER
"Rising adoption of radioligand therapy in oncology"
Demand for Lu-177 is rising as radioligand therapy becomes a standard option for patients with metastatic prostate cancer and gastroenteropancreatic neuroendocrine tumors. Pluvicto is administered at 7.4 GBq per cycle for up to 6 cycles, while Lutathera is given in 4 cycles. Every treatment cycle requires freshly produced isotope. This explains why nuclear therapy accounts for 83.2% of the market and why producers keep expanding reactor access.
RESTRAINT
"Limited availability of enriched ytterbium-176"
Non-carrier-added Lu-177 depends on enriched ytterbium-176, a precursor that is scarce and costly to separate. Natural ytterbium contains only 12.9% of this isotope, so enrichment requires specialized centrifuge or laser-based technology. Because non-carrier-added material holds a 71.5% share, any shortage of precursor directly limits output. Smaller producers without secured enrichment contracts face delays in scaling commercial-grade supply.
OPPORTUNITY
"Expansion into new tumor indications and emerging regions"
Clinical programs are testing Lu-177 conjugates in additional cancers, including kidney, breast, and brain tumors. These programs could multiply the number of doses needed per patient population. Regional growth also offers openings, since Asia Pacific holds a 19.4% share and Middle East & Africa holds 5.2%, with distribution partnerships improving access. Producers that secure long-term supply contracts with drug developers early can lock in demand as new therapies progress toward approval.
CHALLENGE
"Complex logistics and strict manufacturing compliance"
Lu-177 decays with a half-life of 6.65 days, so every shipment must reach treatment centers within a narrow time window. Producers must run weekly production schedules, coordinate air freight, and meet cGMP standards for radiopharmaceutical precursors. Customs delays or reactor shutdowns can interrupt treatment for patients. Maintaining high radionuclidic purity, such as 99.9% for premium non-carrier-added products, also raises quality control costs across the supply chain.
Lutetium-177 (Lu-177) Market Segmentation
The Lu-177 market is segmented by type and application, highlighting how production methods and clinical requirements influence market demand. By type, non-carrier-added Lu-177 dominates the market, followed by carrier-added Lu-177, reflecting growing preference for high-purity radioisotopes in targeted radioligand therapy. By application, nuclear therapy holds the leading position, while research, preclinical studies, and dosimetry development contribute to overall market demand. This segmentation supports manufacturers, nuclear pharmacies, and pharmaceutical developers in optimizing production capacity, improving isotope availability, and addressing expanding therapeutic requirements worldwide.
By Type
Based on Type the global market can be categorized in to Non-carrier-added and Carrier-added.
- Non-carrier-added: This segment holds a 71.5% share because the product is made by irradiating ytterbium-176, then chemically separating Lu-177 from the target. The result is high specific activity and purity above 99.9%, which supports consistent radiolabeling of peptides and antibodies. It also avoids lutetium-177m contamination. Leading suppliers invest in dedicated cGMP facilities, making this segment the preferred choice for commercial radioligand therapies and late-stage clinical trials.
- Carrier-added: This segment accounts for 28.5% of the market and is produced by neutron irradiation of lutetium-176, which has a natural abundance of only 2.6%. The final product contains non-radioactive lutetium and small amounts of lutetium-177m. It remains in use for research, early development, and established workflows where lower cost matters. However, its lower specific activity limits adoption in newer radioligand programs.
By Application
Based on Application the global market can be categorized in to Nuclear Therapy and Others.
- Nuclear Therapy: Nuclear therapy leads with an 83.2% share because Lu-177 is used in approved treatments for prostate cancer and neuroendocrine tumors. Its gamma emission at 208 keV allows post-treatment imaging and dosimetry. Each patient receives multiple cycles, so recurring isotope demand supports stable production planning for hospitals and manufacturers.
- Others: Other applications hold a 16.8% share and include preclinical research, theranostic development, radiolabeling studies, and dosimetry modeling. Academic institutions and biotechnology companies use small batches to test new targeting molecules before moving into clinical programs.
Lutetium-177 (Lu-177) Market Regional Outlook
-
North America
North America holds a 41.3% share of the market, making it the largest regional contributor. The United States drives demand through FDA-approved radioligand therapies, a dense network of nuclear medicine centers, and domestic production. SHINE Technologies operates a Cassiopeia facility in Wisconsin with a capacity of 100,000 doses per year, strengthening local supply security. Canada adds to regional strength through reactor-based isotope programs, including supply arrangements that use Bruce Power reactors. Novartis also runs radioligand manufacturing operations in Indianapolis. Strong clinical trial activity and growing treatment center capacity continue to support demand for non-carrier-added Lu-177 across the region.
-
Europe
Europe accounts for a 29.6% share, supported by centralized regulatory pathways through the European Medicines Agency and early adoption of radioligand therapy. Germany is home to major isotope companies, including Eckert & Ziegler Strahlen and ITM, which supply non-carrier-added Lu-177 to drug developers across the continent. The Netherlands plays a major role through the Petten reactor and its partnership with Curium to expand Lu-177 output. Treatment centers in Germany, France, Italy, and the United Kingdom are adding capacity, which raises demand for regular weekly isotope shipments and strengthens local manufacturing partnerships.
-
Asia Pacific
Asia Pacific holds a 19.4% share and is gaining momentum as hospitals in Japan, South Korea, China, and Australia expand theranostic services. ANSTO supplies Lu-177 from the OPAL reactor in Australia, which operates at 20 MW and supports regional radiopharmaceutical development. Distribution partnerships are widening access. Primo Biotechnology holds exclusive distribution rights for SHINE’s Ilumira in Taiwan, with sales rights in Japan, South Korea, and Singapore. Rising cancer incidence, growing nuclear medicine infrastructure, and government support for radiopharmaceutical research are expected to keep regional demand rising.
-
Middle East & Africa
Middle East & Africa represents a 5.2% share, anchored by South Africa, where NTP Radioisotopes produces non-carrier-added Lu-177 using the SAFARI-1 reactor. The company serves the local market and other agreed territories through a license with ITM. The Gulf region is improving access through distribution partnerships, including an agreement between SHINE and Modawina Medical Company to supply Ilumira in the United Arab Emirates. Investments in hospital-based nuclear medicine and cancer centers are creating gradual demand, although limited local radiopharmaceutical manufacturing still requires imports.
-
Rest of the World
Rest of the World contributes a 4.5% share, led by Latin America, where Brazil and Argentina operate research reactors and nuclear medicine programs. Growth depends on imports of non-carrier-added Lu-177, which are sensitive to the 6.65-day half-life and air freight schedules. Public hospitals and private cancer centers are gradually introducing peptide receptor radionuclide therapy for neuroendocrine tumors. Regional isotope agencies are exploring local production and training programs. As reimbursement frameworks mature and more patients gain access to radioligand therapy, demand for Lu-177 is expected to widen steadily.
Key Industry Players
The competitive landscape combines established pharmaceutical groups, reactor-based isotope producers, and specialized radiopharmaceutical suppliers. Major vendors focus on securing ytterbium-176 supply, expanding cGMP capacity, and signing multi-year agreements with drug developers. Emerging players differentiate through domestic production, regional distribution partnerships, and licensing. Companies with integrated production from precursor to finished isotope hold stronger positioning on quality, timing, and supply reliability.
List of Top Lutetium-177 (Lu-177) Companies
- Advanced Accelerator Applications (Novartis)
- Eckert & Ziegler Strahlen
- SHINE Technologies
- ANSTO
- NTP Radioisotopes
Investment Analysis and Opportunities
Investment in the Lu-177 market is concentrated on production capacity, precursor security, and regional distribution. SHINE Technologies reports potential expansion of its Cassiopeia facility from 100,000 to 200,000 doses per year, showing how producers are preparing for growing therapy volumes. Funding is also directed toward ytterbium-176 enrichment, since a stable precursor supply determines how quickly non-carrier-added output can scale.
Opportunities are strongest in companies that combine reactor access, cGMP manufacturing, and long-term supply agreements with radiopharmaceutical developers. Partnerships with distributors in Asia Pacific and the Middle East create new routes to market. Investors also see value in contract manufacturing, recycling of enriched ytterbium, and logistics services that protect isotope activity during transit.
New Product Development
Product development in the Lu-177 market focuses on higher purity, better scalability, and branded isotope offerings. SHINE Technologies markets Ilumira, a non-carrier-added Lu-177 product with radionuclidic purity of at least 99.9%, produced under cGMP and aligned with European Pharmacopeia standards. Eckert & Ziegler Strahlen supplies GMP-grade non-carrier-added Lu-177 for research and clinical use, supporting global trial programs.
Developers are also designing new Lu-177 conjugates for prostate cancer, neuroendocrine tumors, and other solid tumors. Established therapies use 7.4 GBq per cycle, so manufacturers are optimizing batch size, radiochemical yield, and shelf life. Reactor-based innovations, such as improved ytterbium-176 targets and recycling processes, are helping suppliers deliver steady weekly output.
Recent Developments
- May 2026:
SHINE Technologies secures European centralized marketing authorization for its non-carrier-added Lu-177 product Ilumira.SHINE Technologies obtained European authorization for Ilumira to enable EU sales, strengthening global reach through proprietary non-carrier-added production at its Cassiopeia facility in Wisconsin.
- October 2024:
NTP Radioisotopes renews technology license with ITM and signs new supply agreement for non-carrier-added Lu-177. NTP Radioisotopes extended its license for ITM intellectual property and began a supply agreement, aiming to expand capacity using ytterbium-176 irradiation in the SAFARI-1 reactor.
- September 2023:
Eckert & Ziegler signs 10-year supply agreement for carrier-free Lu-177 with POINT Biopharma.Eckert & Ziegler agreed to supply non-carrier-added Lu-177 to POINT Biopharma, securing long-term demand for its GMP-grade production and supporting prostate cancer radioligand clinical candidates.
Report Coverage
This report covers the global Lu-177 market across 2 types, 2 applications, and 5 regions. It examines production routes, supply chain structure, regulatory progress, and demand drivers linked to radioligand therapy in oncology.
The study profiles 5 leading companies and evaluates their capacity expansion, licensing, and distribution strategies. It also reviews segment shares, regional performance, market dynamics, and product innovation to support strategic planning for isotope producers, drug developers, and investors.
Lutetium-177 (Lu-177) Market Market Report Scope & Segmentation
| REPORT COVERAGE | DETAILS |
|---|---|
| Market Size Value In | USD 2880.71 Million in 2026 |
| Market Size Value By | USD 11559.76 Million by 2035 |
| Growth Rate | CAGR of 16.9% from 2026-2035 |
| Forecast Period | 2026 - 2035 |
| Base Year | 2025 |
| Historical Data Available | Yes |
| Regional Scope | Global |
| Segments Covered |
By Type
Non-carrier-added | Carrier-added
By Application
Nuclear Therapy | Others
|
Frequently Asked Questions
OUR
CLIENTS